Auronext Pharma Private Limited, a amalgamated private limited company, was established on 02 July 2009 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U74999TG2009PTC109591. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹255.00 Cr and a paid-up capital of ₹124.98 Cr.
It upholds a compliant status. Employing 293 professional, Its leadership includes Madan Mohan Reddy Mettu (Director), Sapna (Director), Jacob Joseph (Whole-Time Director). Past directors included Vinod Kumar Reddy Aerva, Bodh Raj Sikri, Govindarajan Narayanan. It holds no open charges and ₹36.50 Cr settled loans. Its latest AGM occurred on 19 June 2023, with the balance sheet filed on 31 March 2023. It is based at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmak, Tha, Hyderabad, Telangana, 500032.
U74999TG2009PTC109591
109591
02 July 2009
₹255.00 Cr
₹124.98 Cr
Roc Hyderabad
Unlisted
Amalgamated
Explore comprehensive insights into Auronext Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Madan Mohan Reddy Mettu | Director | 31 Aug 2020 | Current |
| Sapna | Director | 23 May 2019 | Current |
| Jacob Joseph | Whole-Time Director | 01 Jul 2021 | Current |
| Venkata Radhakrishna Racharla | Company Secretary | 15 Apr 2019 | Current |
| Sarath Chandra Reddy Penaka | Director | 20 Aug 2009 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 04 Nov 2017 | Past |
| Pramod Abcsdd | Director | 21 Aug 2020 | Past |
| Pramod Abcsdd | Director | 01 Oct 2015 | Past |
| Pramod Abcsdd | Director | 31 Aug 2020 | Past |
| Pramod Abcsdd | Additional Director | 24 Aug 2021 | Past |
| Pramod Abcsdd | Director | 31 Aug 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Auronext Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.87% increase. The company also saw a substantial improvement in profitability, with a 49.22% increase in profit. The company's net worth dipped by a decrease of 1.47%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Auronext Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹365,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jul 2016 | Yes Bank Limited | ₹35.00 Cr | Satisfied |
| 02 Feb 2010 | Axis Bank Limited | ₹1.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Auronext Pharma has a workforce of 293 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Auronext Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auronext Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Auronext Pharma Private Limited last Annual general meeting of members was held on 19 Jun 2023 as per latest MCA records. was completed.
Auronext Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad. was recorded as a recent event.
Progress on Ravi Kiran Yellapragada was appointed as a CFO was appointed as a CFO on 01 Jul 2021 & has been associated with this company since 4 years 4 months . was documented.
Jacob Joseph was appointed as a Whole-time director was appointed as a Whole-time director on 01 Jul 2021 & has been associated with this company since 4 years 4 months . was recorded as a recent event.
Progress on A charge registered on 21 Jul 2016 via Charge ID 100058300 with Yes Bank Limited was fully satisfied on 08 Feb 2021. was documented.
Progress on Madan Mohan Reddy Mettu was appointed as a Director was appointed as a Director on 31 Aug 2020 & has been associated with this company since 5 years 2 months . was documented.
FDA: Aurobindo Pharma's manufacturing facility has incomplete and misleading documents. They also found issues with quality control and training. Equipment is not cleaned properly. Aurobindo says they will fix it. FDA inspected from Sept 19-27 and issued warning letter for other facility. Aurobindo's stock went down..
The CIN of Auronext Pharma Private Limited is U74999TG2009PTC109591.
Auronext Pharma Private Limited is headquartered at Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmak, Tha, Hyderabad, Telangana, 500032.
Auronext Pharma Private Limited was incorporated on 02 July 2009.
The current directors of Auronext Pharma Private Limited are
The primary industry of Auronext Pharma Private Limited is Manufacturing.
Auronext Pharma Private Limited is unlisted.
The authorized capital of Auronext Pharma Private Limited is ₹255.00 Cr, and the paid-up capital is ₹124.98 Cr.
The compliance status of Auronext Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX